泛亚洲改编ESMO转移性结直肠癌管理共识指南:JSMO-ESMO倡议
该指南由ESMO与JSMO发起,经CSCO、KACO、MOS、SSO和TOS认可,旨在将2016年ESMO转移性结直肠癌共识指南改编至亚洲人群。改编考虑亚洲族裔在特定系统治疗毒性等方面的差异,由六国/地区肿瘤学会专家投票形成共识,投票基于科学证据,独立于各国现行实践及药物可及性与报销情况。
要点
- 指南为2016年ESMO mCRC共识指南的泛亚洲改编版。
- 改编重点考虑亚洲族裔在系统治疗毒性等方面的差异。
- 共识由日本、中国、韩国、马来西亚、新加坡及台湾地区专家投票形成。
核心结论
- 形成适用于亚洲mCRC患者的泛亚洲改编ESMO共识指南。
研究设计与样本
- 由ESMO与JSMO发起、六国/地区肿瘤学会认可的专家共识会议,投票基于科学证据。
临床怎么用
- 供亚洲肿瘤内科医生在mCRC系统治疗决策时参考该泛亚洲共识推荐。
局限性
- 投票独立于各国现行治疗实践及药物可及性与报销情况。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The most recent version of the European Society for Medical Oncology (ESMO) consensus guidelines for the treatment of patients with metastatic colorectal cancer (mCRC) was published in 2016, identifying both a more strategic approach to the administration of the available systemic therapy choices, and a greater emphasis on the use of ablative techniques, including surgery. At the 2016 ESMO Asia Meeting, in December 2016, it was decided by both ESMO and the Japanese Society of Medical Oncology (JSMO) to convene a special guidelines meeting, endorsed by both ESMO and JSMO, immediately after the JSMO 2017 Annual Meeting. The aim was to adapt the ESMO consensus guidelines to take into account the ethnic differences relating to the toxicity as well as other aspects of certain systemic treatments in patients of Asian ethnicity. These guidelines represent the consensus opinions reached by experts in the treatment of patients with mCRC identified by the Presidents of the oncological societies of Japan (JSMO), China (Chinese Society of Clinical Oncology), Korea (Korean Association for Clinical Oncology), Malaysia (Malaysian Oncological Society), Singapore (Singapore Society of Oncology) and Taiwan (Taiwan Oncology Society). The voting was based on scientific evidence and was independent of both the current treatment practices and the drug availability and reimbursement situations in the individual participating Asian countries.
引用
- Yoshino T, Arnold D, Taniguchi H, et al. Pan-Asian adapted ESMO consensus guidelines for the management of patients with metastatic colorectal cancer: a JSMO-ESMO initiative endorsed by CSCO, KACO, MOS, SSO and TOS. Ann Oncol. 2018. PMID: 29155929. doi:10.1093/annonc/mdx738
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。